Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan R Brody

Showing results (111-120 of 170) with videos related to

Pageof 17
Sort By:
Cancer|March 27, 2018
A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancerMichael J Pishvaian, Rebecca S Slack, Wei Jiang, et al.
RNA Biology|June 29, 2013
HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancerRichard A Burkhart, Danielle M Pineda, Saswati N Chand, et al.
Cancer Letters|September 5, 2025
Nuclear cGAS mediated Replication Stress and Mitotic Catastrophe can Overcome Gemcitabine ResistanceSoon Young Park, Kang Jin Jeong, Alfonso Poire, et al.
Oncotarget|September 28, 2016
Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesisFernando F Blanco, Ranjan Preet, Andrea Aguado, et al.
Cancer Research|January 22, 2009
Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influenceJonathan R Brody, Tomas Hucl, Christina L Costantino, et al.
Cancer Research|November 6, 2013
Targeting PARP-1 allosteric regulation offers therapeutic potential against cancerJamin D Steffen, Renee M Tholey, Marie-France Langelier, et al.
Molecular Cancer Therapeutics|December 28, 2020
Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic PropertiesWilliam H Gmeiner, Anthony Dominijanni, Alex O Haber, et al.
NAR Cancer|April 24, 2023
Deletion of the mRNA stability factor <i>ELAVL1</i> (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrityGrace A McCarthy, Roberto Di Niro, Jennifer M Finan, et al.
Oncotarget|August 29, 2015
Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cellsMasaya Jimbo, Fernando F Blanco, Yu-Hung Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumorMichiel S van der Heijden, Jonathan R Brody, David A Dezentje, et al.
Pageof 17

Showing results (111-120 of 170) with videos related to

Sort By:
Pageof 17
Cancer|March 27, 2018
A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancerMichael J Pishvaian, Rebecca S Slack, Wei Jiang, et al.
RNA Biology|June 29, 2013
HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancerRichard A Burkhart, Danielle M Pineda, Saswati N Chand, et al.
Cancer Letters|September 5, 2025
Nuclear cGAS mediated Replication Stress and Mitotic Catastrophe can Overcome Gemcitabine ResistanceSoon Young Park, Kang Jin Jeong, Alfonso Poire, et al.
Oncotarget|September 28, 2016
Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesisFernando F Blanco, Ranjan Preet, Andrea Aguado, et al.
Cancer Research|January 22, 2009
Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influenceJonathan R Brody, Tomas Hucl, Christina L Costantino, et al.
Cancer Research|November 6, 2013
Targeting PARP-1 allosteric regulation offers therapeutic potential against cancerJamin D Steffen, Renee M Tholey, Marie-France Langelier, et al.
Molecular Cancer Therapeutics|December 28, 2020
Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic PropertiesWilliam H Gmeiner, Anthony Dominijanni, Alex O Haber, et al.
NAR Cancer|April 24, 2023
Deletion of the mRNA stability factor <i>ELAVL1</i> (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrityGrace A McCarthy, Roberto Di Niro, Jennifer M Finan, et al.
Oncotarget|August 29, 2015
Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cellsMasaya Jimbo, Fernando F Blanco, Yu-Hung Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumorMichiel S van der Heijden, Jonathan R Brody, David A Dezentje, et al.
Pageof 17